Drug Trial Radar · NCT04322149
Multiple Doses of AT-1501-A201 in Adults With ALS
Last checked: Nov 19, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Oct 16, 2020
Primary completion
Mar 24, 2022
Study completion Mar 24, 2022
Sponsor
- Lead sponsor
- Anelixis Therapeutics, LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites. Participants will be enrolled into one of four ascending doses.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
AT-1501Drug
AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Up to 18 Weeks
- Safety and TolerabilityTime frame: Up to 18 Weeks
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Barrows Neurological Institute
Phoenix, Arizona
University of California Irvine
Orange, California
California Pacific Medical Center
San Francisco, California
Augusta University
Augusta, Georgia
University of Indiana
Indianapolis, Indiana
The University of Kansas Medical Center
Kansas City, Kansas
Johns Hopkins University Medical Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Hospital for Special Surgery (HSS)
New York, New York
Providence Brain & Spine Institute
Portland, Oregon
Texas Neurology, P.A.
Dallas, Texas
Houston Methodist Neurological Institute
Houston, Texas
Montreal Neurological Institute and Hospital
Montreal, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.